Bank of America analysts raised their price target for Eli Lilly, projecting that overseas obesity-treatment sales could eventually exceed those in the U.S. [1].
This shift in projection highlights the expanding global demand for GLP-1 medications. As these treatments move beyond North American markets, the scale of international patient populations may redefine the company's primary revenue streams.
Analysts based this outlook on the rapid adoption of obesity drugs abroad. They said that pricing dynamics and the growth of eligible patient populations outside the U.S. are creating a significant opportunity for the company's GLP-1 franchise [1].
"We see the overseas obesity market as a longer‑term growth engine that could eventually eclipse the U.S. market for Eli Lilly’s GLP‑1 franchise," a BofA analyst said [1].
The analysis follows the company's most recent earnings release, which detailed second-quarter results reported in July 2024 [1]. While the specific new price target figure was not disclosed in the report, the upgrade signals strong confidence in the company's international trajectory [1].
Global expansion remains a priority for pharmaceutical firms as they navigate different regulatory environments, and pricing structures across various continents. For Eli Lilly, the ability to scale production and distribution to meet this international demand will be critical to achieving these projections [1].
“Overseas obesity sales could eventually exceed those in the U.S.”
The projection suggests a pivot in the pharmaceutical industry where the U.S. is no longer the sole dominant driver of growth for blockbuster drugs. If international markets eclipse domestic sales, Eli Lilly will face increased exposure to foreign currency fluctuations and the diverse pricing regulations of global healthcare systems.
